Henry Okoroike
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Henry Okoroike has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Afsin Oktay
Rush University Medical Center
2 shared publications Faisal Hasan
1 shared publicationJennifer Austin Szwak
Department of Pharmacy, Johns Hopkins Hospital, Baltimore, Maryland
1 shared publication- Marisol Wences
University of Chicago Medical Center
1 shared publication Pamela Simone
Department of Pharmacy, University of Chicago Medicine, Chicago, Illinois
1 shared publicationRachel Lavelle
Department of Pharmacy, University of Chicago Medicine, Chicago, Illinois
1 shared publication
Latest Publications
- Open Access
- 3 September 2026
- Published by Elsevier in The American Journal of Cardiology
- Vol. 278, 70-74
Early Low-Density Lipoprotein Cholesterol Target Attainment Is Associated With Fewer Recurrent Cardiovascular Events After Acute Myocardial Infarction: A Real-World Cohort Study
- 3 September 2026
- Published by Elsevier in The American Journal of Cardiology
- Vol. 278, 70-74
Open AccessEarly Low-Density Lipoprotein Cholesterol Target Attainment Is Associated With Fewer Recurrent Cardiovascular Events After Acute Myocardial Infarction: A Real-World Cohort Study
- Open Access
- 2 June 2026
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 8 (2) , 96-101
Validation of a novel Guideline Directed Medical Therapy (GDMT) scoring tool to optimize therapy for patients with heart failure with reduced ejection fraction (HFrEF)
Background: The mortality benefit of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) is well established. However, contemporary registry data consistently demonstrates substantial gaps in GDMT optimization. A standardized tool to quantify GDMT optimization and target dose achievement may help identify treatment deficits, guide clinical decision-making, and improve associated patient outcomes. Methods: This retrospective, single-center observational study evaluated the internal validity of a novel GDMT scoring tool to quantify GDMT optimization. Adult patients admitted between September 2022 and September 2023 with HFrEF and outpatient follow-up were included. The primary analysis assessed the association between GDMT optimization at 30 days and the risk of 90-day all-cause hospitalization using multivariable logistic regression. Secondary analyses described GDMT optimization rates at 30 days, quadruple therapy rates, and associations between GDMT optimization and 90-day HF hospitalization and all-cause mortality. Results: Eighty-nine patients met inclusion criteria. At 30 days, 76% of patients (n= 68) achieved a GDMT score of ≥ 5 and 24% (n= 21) had a suboptimal GDMT score of P=0.008 ) though no significant differences were observed for HF hospitalizations (OR 0.55 CI 0.17-1.85, P=0.33 ) or all-cause mortality ( P=0.997 ). Conclusion: An optimized GDMT score of ≥ 5 at 30 days was associated with reduced odds of all-cause readmissions at 90 days ( P=0.008 ).
- 2 June 2026
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 8 (2) , 96-101
Open AccessValidation of a novel Guideline Directed Medical Therapy (GDMT) scoring tool to optimize therapy for patients with heart failure with reduced ejection fraction (HFrEF)
Background: The mortality benefit of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) is well established. However, contemporary registry data consistently demonstrates substantial gaps in GDMT optimization. A standardized tool to quantify GDMT optimization and target dose achievement may help identify treatment deficits, guide clinical decision-making, and improve associated patient outcomes. Methods: This retrospective, single-center observational study evaluated the internal validity of a novel GDMT scoring tool to quantify GDMT optimization. Adult patients admitted between September 2022 and September 2023 with HFrEF and outpatient follow-up were included. The primary analysis assessed the association between GDMT optimization at 30 days and the risk of 90-day all-cause hospitalization using multivariable logistic regression. Secondary analyses described GDMT optimization rates at 30 days, quadruple therapy rates, and associations between GDMT optimization and 90-day HF hospitalization and all-cause mortality. Results: Eighty-nine patients met inclusion criteria. At 30 days, 76% of patients (n= 68) achieved a GDMT score of ≥ 5 and 24% (n= 21) had a suboptimal GDMT score of P=0.008 ) though no significant differences were observed for HF hospitalizations (OR 0.55 CI 0.17-1.85, P=0.33 ) or all-cause mortality ( P=0.997 ). Conclusion: An optimized GDMT score of ≥ 5 at 30 days was associated with reduced odds of all-cause readmissions at 90 days ( P=0.008 ).